Omada Health just jumped 21.2% in a single session, and that move highlights how sharply expectations have flipped. A stock that had been grinding higher over the past quarter suddenly traded like a high growth software winner following its Q2 report.

The headline is simple. Omada Health reported roughly US$88 million in revenue and about US$5.3 million in net income, its second straight quarter in the black. For a digital health company long treated as a scale first, profits later story, this quarter was about margins and cash discipline finally showing up in the earnings line.

Is Omada Health now a genuine bargain after this profit turn, or just a richly priced stock riding momentum? Compare the current share price to cash flow based fair value in the valuation analysis for Omada Health.

Q2 2026 Earnings Summary

• Revenue (Q2 2026 vs. Q2 2025): US$87.8 million vs. US$61.4 million (up about 43%)
• Net Income (Q2 2026 vs. Q2 2025): Profit of US$5.3 million vs. loss of US$5.3 million (swing back to profit)
• Basic EPS (Q2 2026 vs. Q2 2025): US$0.09 per share vs. loss of US$0.24 per share (return to positive earnings per share)
• Gross Margin (Q2 2026 vs. Q2 2025): 73% GAAP vs. about 66% GAAP (expansion of roughly 700 basis points)

Prefer clean charts instead of scrolling through another wall of earnings numbers? Check the full visual breakdown of Omada Health, including its recent profitability trend, in the company report for Omada Health.

Omada bullish thesis: margins, scale and GLP‑1 mix

Optimists argue Omada Health can be a scaled virtual chronic care platform, with GLP‑1 drugs and AI tools lifting revenue per member and margins. Q2 does support the margin part of that story. GAAP gross margin reached 73% and cost to serve per member fell by more than 10%. Non GAAP operating expenses dropped from 68% to 62% of revenue and Omada posted a second straight GAAP profit with US$5.3 million of net income and about US$11 million of adjusted EBITDA. That is real progress on operating leverage. The GLP‑1 piece looks more balanced. Management described GLP‑1 members as under 20% of the base and said diabetes and hypertension grew faster than the company overall. The bullish idea that Omada is a single product GLP‑1 story is not supported. The broader cardiometabolic bundle is doing more of the work.

Omada bearish thesis: GLP‑1 risk and profit durability

Bears worry Omada Health is overexposed to GLP‑1 policy risk, investing heavily in AI and prescribing without clear returns, and that profits are fragile. Q2 partly pushes back. GLP‑1 membership has “roughly held constant” at under 20% of members, while other cardiometabolic programs grew faster than revenue. That weakens the idea of a single drug dependency. AI tools are already tied to lower care delivery cost and higher gross margin, so they are not just an expense line. On the other hand, management flagged uncertainty around employer GLP‑1 coverage and seasonality, and the growth story now leans more on future launches such as cholesterol and prescribing in 2027. The CEO transition scheduled for 2027 and recent insider share sale add governance questions that bears will keep on their list, even with the current profitability milestone.

After a sharp price move, a CEO transition on the horizon and recent insider selling, it is worth asking if these are isolated flags or early signs of deeper fragility. Review the structured risk analysis for Omada Health which shows 2 important warning signs.

Stay Ahead With Simply Wall St

Omada Health just swung to back to back profits and a 21.2% one day move can make timing your entry tricky. Register for free with Simply Wall St and add Omada Health to your Watchlist to track price against fair value and watch for a setup that fits your plan. After you buy, keep your decisions grounded with the Portfolio Command Center so you see only focused updates on the holdings that matter most. Then use the Community to see how other investors are thinking about the same risks and catalysts, so you can spot potential turning points early and aim to stay ahead of the market.

Seeking Alternatives Beyond Omada Health?

Fresh stock ideas can move from quiet to flying once momentum builds. Use these curated lists before the crowd catches on and while it matters. Act now.

• Spot companies quietly building strength before a potential breakout by scanning the 19 high quality undiscovered gems that currently sit under the radar for now.
• Target durable cash generators that may hold up when sentiment swings by reviewing the curated 78 resilient stocks with low risk scores for resilient balance sheets and steadier profiles.
• Ride the structural shift into smarter infrastructure by checking the focused 36 power grid technology and infrastructure stocks as grids upgrade for reliability and new demand patterns.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.